Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079357 | 1.00 | CXCR3 (0.44) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079223 | 0.94 | CXCR3 (0.46) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079231 | 0.94 | CXCR3 (0.46) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079504 | 0.93 | CCR3 (0.45) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079514 | 0.93 | CCR3 (0.45) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079687 | 0.92 | CXCR3 (0.50) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079676 | 0.92 | CXCR3 (0.50) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079793 | 0.91 | CCR3 (0.49) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6079782 | 0.91 | CCR3 (0.49) | CXCR3CCR3DCUN1D1KMT2ADRD2 | |
| SCHEMBL6078760 | 0.88 | CCR3 (0.52) | CXCR3CCR3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | claimed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | claimed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | CXCR3 3447/4885CCR3 3917/4885DCUN1D1 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.